Commercial Insight: Antihormonal Therapies Aromatase Inhibitors Reinvigorate a Mature Market

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2005-07-08

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The antihormonal cancer therapy market is characterized by a mature nature and a relatively high level of saturation. Despite this, growth will continue slowly at a CAGR of 0.9% during 2004-14, with those areas in decline offset by clear potential from new products and line extensions. Generic competition continues to threaten, although effective lifecycle management can dilute the overall impact.


Scope

  • Overview of the current antihormonal therapies market, including profiles of key products and events impacting each during 2004-14
  • Assessment of current and future opportunities and threats in the antihormonal therapies market across the seven major pharmaceutical markets
  • Individual country, EU5 and global sales from 2004 to 2014 for branded products and generics
  • Detailed discussion of assumptions and events used in our forecast analysis, plus commercial impact and lifecycle management case studies


    • Report Highlights
    The antihormonal therapies market was worth $4.8 billion in 2004, and is set to grow at a CAGR of 0.9% to reach $5.5 billion by 2014. This is due to the maturity of the market and its relative saturation, as well as the increasing threat of key patent expiries and entry of generic competition.

    Despite the decline of some therapy classes, opportunities for new growth do exist. The aromatase inhibitors will drive significant market expansion, particularly in light of recent positive clinical trial data and ASCO recommendations that will serve to increase their profile and significantly increase uptake.

    The remaining drug classes within the antihormonal therapies market will see a decline in sales growth, although volume is expected to remain more or less stable. Despite generic competition, the maturity and saturated nature of this market means further pipeline breakthroughs are unlikely unless significant clinical superiority is demonstrated.


    Reasons to Purchase

  • Understand market specific drivers and predict the future potential of key antihormonal therapies
  • Quantify the impact of key patent expiries, product launches and clinical trial results
  • Adopt knowledge to drive strategic planning for mature products and optimize the market penetration of new entrants

    • Table of Contents

    Other users found this report page using the following search terms: antihormonal tamoxifen market eligard cancer plenaxis tamoxifen breast lupron lhrh current uk

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.